[go: up one dir, main page]

WO2018125019A3 - Use of some mirnas for the diagnosis and treatment of diseases associated with insulin - Google Patents

Use of some mirnas for the diagnosis and treatment of diseases associated with insulin Download PDF

Info

Publication number
WO2018125019A3
WO2018125019A3 PCT/TR2017/050737 TR2017050737W WO2018125019A3 WO 2018125019 A3 WO2018125019 A3 WO 2018125019A3 TR 2017050737 W TR2017050737 W TR 2017050737W WO 2018125019 A3 WO2018125019 A3 WO 2018125019A3
Authority
WO
WIPO (PCT)
Prior art keywords
mir
insulin
diagnosis
treatment
mirnas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2017/050737
Other languages
French (fr)
Other versions
WO2018125019A2 (en
Inventor
Selda OKTAYOĞLU
Ediz COŞKUN
Merve ERCIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istanbul Ueniversitesi
Original Assignee
Istanbul Ueniversitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istanbul Ueniversitesi filed Critical Istanbul Ueniversitesi
Publication of WO2018125019A2 publication Critical patent/WO2018125019A2/en
Publication of WO2018125019A3 publication Critical patent/WO2018125019A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to the use of at least one microRNA selected from the group consisting of miR-18a, miR-19b, miR-30d, miR-124, miR-146a, miR-184, miR-335, miR-433-5p and miR-503, or a DNA, mRNA or IncRNA thereof, in the diagnosis and treatment of insulin-related diseases such as diabetes mellitus and obesity.
PCT/TR2017/050737 2016-12-30 2017-12-31 Use of some mirnas for the diagnosis and treatment of diseases associated with insulin Ceased WO2018125019A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
TR2016/20327 2016-12-30
TR201620292 2016-12-30
TR2016/20292 2016-12-30
TR2016/20274 2016-12-30
TR201620274 2016-12-30
TR201620327 2016-12-30

Publications (2)

Publication Number Publication Date
WO2018125019A2 WO2018125019A2 (en) 2018-07-05
WO2018125019A3 true WO2018125019A3 (en) 2018-09-20

Family

ID=61024547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2017/050737 Ceased WO2018125019A2 (en) 2016-12-30 2017-12-31 Use of some mirnas for the diagnosis and treatment of diseases associated with insulin

Country Status (1)

Country Link
WO (1) WO2018125019A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7638967B2 (en) * 2019-08-26 2025-03-04 ピリオド ピル ベーフェー Treatment of menstrual cycle symptoms
WO2022060178A1 (en) * 2020-09-21 2022-03-24 고려대학교 산학협력단 Method for prediction of recurrence or prognosis of diabetic foot ulcer by using specific methylation of gene
KR102581240B1 (en) * 2020-09-21 2023-09-22 고려대학교 산학협력단 Method of predicting Diabetic Foot Ulcer Recurrence or Prognostics using Specific Methylation of gene
US20230364153A1 (en) * 2020-09-24 2023-11-16 Research & Business Foundation Sungkyunkwan University Method for direct reprogramming from somatic cells into pancreatic beta cells by using microrna, and differentiation composition
CN113122536B (en) * 2021-03-31 2023-06-20 南通大学 A long non-coding RNA that promotes the differentiation of neural stem cells into neurons and its screening method
CN113774127B (en) * 2021-09-24 2022-06-24 南京医科大学 Application of serum extracellular vesicle miR-503-5p in preparation of diagnostic kit for onset of type 2diabetes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078558A2 (en) * 2010-12-06 2012-06-14 Rush University Medical Center microRNAs AS NEW THERAPEUTIC TARGETS FOR THE PREVENTION AND/OR TREATMENT OF RETINOPATHY
WO2014135653A1 (en) * 2013-03-06 2014-09-12 Royal College Of Surgeons In Ireland Diagnosis and treatment of metabolic disorders
WO2015095116A1 (en) * 2013-12-17 2015-06-25 Rush University Medical Center Compositions and methods for treating diabetic nephropathy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078558A2 (en) * 2010-12-06 2012-06-14 Rush University Medical Center microRNAs AS NEW THERAPEUTIC TARGETS FOR THE PREVENTION AND/OR TREATMENT OF RETINOPATHY
WO2014135653A1 (en) * 2013-03-06 2014-09-12 Royal College Of Surgeons In Ireland Diagnosis and treatment of metabolic disorders
WO2015095116A1 (en) * 2013-12-17 2015-06-25 Rush University Medical Center Compositions and methods for treating diabetic nephropathy

Also Published As

Publication number Publication date
WO2018125019A2 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
WO2018125019A3 (en) Use of some mirnas for the diagnosis and treatment of diseases associated with insulin
WO2014116729A3 (en) Haplotying of hla loci with ultra-deep shotgun sequencing
WO2009108856A3 (en) Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
WO2017156015A3 (en) Micrornas and methods of their use
WO2013150082A8 (en) Hybridization-based replication of nucleic acid molecules
WO2013107459A3 (en) Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
JP2016526529A5 (en)
JP2012070736A5 (en)
WO2014052487A8 (en) Two-primer pcr for microrna multiplex assay
WO2009111375A3 (en) Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
WO2015188197A3 (en) Polynucleotide constructs having bioreversible and non-bioreversible groups
WO2007148235A3 (en) Cancer-related nucleic acids
JP2016528887A5 (en)
EP2481805A3 (en) Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
WO2016209862A8 (en) Glucokinase (gck) irna compositions and methods of use thereof
WO2009090639A3 (en) Sirna compounds and methods of use thereof
JP2017502668A5 (en)
HK1213830A1 (en) Biomarkers predictive for clinical response for glatiramer acetate
HK1200274A1 (en) Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
WO2015012541A3 (en) Kit for early diagnosis of alzheimer's dementia
MX2017004973A (en) Methods and compositions for treating a subject with a smad7 antisense oligonucleotide.
HK1212734A1 (en) Markers and methods for detecting posttraumatic stress disorder (ptsd)
WO2015179777A3 (en) Gene expression profiles associated with sub-clinical kidney transplant rejection
WO2012101219A3 (en) Complex mirna sets as novel biomarkers for lung diseases
WO2014124155A3 (en) Methods for inducing cardiomyocyte proliferation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17875073

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17875073

Country of ref document: EP

Kind code of ref document: A2